Polsinelli Represents Sanacor, Inc. in Seed Financing

Polsinelli congratulates its client Sanacor, Inc., on its Seed Financing. Sanacor, Inc. is a biotechnology company focused on mitochondrial dysfunction in diabetic cardiovascular diseases (more than 500 million people are expected to develop diabetic cardiovascular disease by 2045, with associated healthcare costs projected at $350 billion annually).

The financing was led by Venture Investors Health Fund (VI). The financing will help Sanacor move its lead compound forward toward human clinical studies and expand its biological foundation which is committed to finding disease modifying treatments for patients in need.

More information about the financing can be obtained here.

The Polsinelli Venture Capital and Emerging Growth Companies team involved in the transaction included Chris Simpson, Laura Venn and Izzy Drake.